Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    BIIB037
Show Display Options
Rank Status Study
1 Completed Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037;   Other: Placebo
2 Active, not recruiting Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
Condition: Alzheimer's Disease
Intervention: Drug: aducanumab
3 Recruiting 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
4 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
5 Active, not recruiting Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
6 Active, not recruiting Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.